JOURNAL OF THE CZECH PHARMACEUTICAL SOCIETY AND THE SLOVAK PHARMACEUTICAL SOCIETY

Čes. slov. farm. 2017, 66(1):3-8 | DOI: 10.36290/csf.2017.001

Medical and non-medical costs of Parkinson disease - comparison of Europe, USA, Asia an Australia

Petra Marešová1,2,*, Blanka Klímová3, Kamil Kuča4,5
1 University of Hradec Kralove, Faculty of Informatics and Management, Department of Economics, Hradec Králové, Czech Republic
2 Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
3 University of Hradec Kralove, Faculty of Informatics and Management, Czech Republic
4 University of Hradec Kralove, Center for Basic and Applied Research, Czech Republic
5 University Hospital Hradec Kralove, Biomedical Research Center, Czech Republic

At present different kinds of dementia impose a significant economic burden on the whole societies. Parkinson's disease is the second most common type of dementia. The purpose of this study is to analyze the costs of people suffering from Parkinson's disease in the context of public expenditure needs for the affected people. Firstly, the treatment costs and care in the selected European countries are analyzed, and secondly, these data are compared with the data from other countries and continents. The focus is not only on the developed economies where the issue of costs and PD already causes significant expenditure from public budgets, but also on the developing economies. The methods applied in this study include a method of literature search of available sources describing the costs of PD and a qualitative comparative analysis method. The findings show that the data from the European countries range between 1,949 € and 12,054 €. Comparable data are in the USA at 17,064 €, in Australia at 7,020 € and in Asia they range between 649 € and 9,544 €. These values are certainly connected not only with the available data, but also with the level and possibilities of healthcare services in these countries. In addition, GDP for these continents and countries was specified and the cost ratio of patient with respect to GHD per capita was described. This calculation provides an orientation relative indicator about the economic burden with respect to the country's development. The results indicate that the most significant issues are diseases and treatment in the European countries in which their highest incidence is expected in future.

Keywords: Parkinson's disease; costs; health care; analysis
Grants and funding:

This study is supported by internal project SPEV No. 2103 Investment under concept Industry 4.0 at Faculty of Informatics and Management, University of Hradec Kralove, Czech Republic. In addition, authros thank to Michal Hruska for his help with the research.

Received: November 6, 2016; Accepted: January 3, 2017; Published: January 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Marešová P, Klímová B, Kuča K. Medical and non-medical costs of Parkinson disease - comparison of Europe, USA, Asia an Australia. Čes. slov. farm. 2017;66(1):3-8. doi: 10.36290/csf.2017.001.
Download citation

References

  1. Marešová P., Klímová B., Kuča K. Alzheimer's disease: Cost cuts call for novel drugs development and national strategy. Čes. slov. Farm. 2015; 64, 25-30. Go to original source...
  2. Maresova P., Mohleska H., Kuca K. Social and family load of Alzheimer's disease. Applied economics 2015; 48 (21), 1936-1948. doi:10.1080/00036846.2015.1111986 Go to original source...
  3. Mohelska H., Maresova P., Valis M., Kuca K. Alzheimer's disease and its treatment costs: case study in the Czech Republic. Neuropsychiatric Disease and Treatment 2015; (11), 2349-2354. doi:10.2147/NDT.S87503. Go to original source... Go to PubMed...
  4. Mohelská H., Marešová P. Economic and managerial aspects of Alzheimer's disease in the Czech Republic. In: Procedia economics and finance. Amsterdam: Elsevier 2015; 521-524. Go to original source...
  5. The European Brain Council (EBC). Parkinson's disease Fact Sheet 2011. Available at: http://ebc-brussels.org/wp-content/uploads/2015/07/Parkinsons-fact-sheet-July-2011.pdf (accessed 20. 11. 2015).
  6. Statista. Projected worldwide increase in prevalence of Parkinson's disease in 2005 and 2030. 2015. Available at: http://www.statista.com/statistics/215459/projected-worldwide-increase-in-prevalence-of-parkinsons-diseas/ (accessed 20.11. 2015).
  7. LeDuc Media. 2015. Parkinson disease. Available at: http://www.worldlifeexpectancy.com/cause-of-death/parkinson-disease/by-country/(accessed 20.11. 2015).
  8. Pringsheim T, Jette N, Frolkis A, Steeves TD. The prevalence of Parkinson's disease: a systematic review and meta-analysis. Mov Disord. 2014; 29(13), 1583-1590. doi:10.1002/mds.25945 Go to original source... Go to PubMed...
  9. Findley L., Aujla M., Bain P. G., et al. Direct economic impact of Parkinson's disease: a research survey in the United Kingdom. Mov Disord. 2003; 18, 1139-1145. Go to original source... Go to PubMed...
  10. Hagell P., Nordling S., Reimer J., Grabowski M., Persson U. Resource use and costs in a Swedish cohort of patients with Parkinson's disease. Mov Disord. 2002; 17, 1213-1220. Go to original source... Go to PubMed...
  11. Winter Y., Campenhausen S., Brozova H., et al. Costs of Parkinson's disease in Eastern Europe: A Czech cohort study. Parkinsonism 2010; 16(1), 51-56. doi:10.1016/j.parkreldis.2009.07.005. Go to original source... Go to PubMed...
  12. Campenhausen S., Winter Y., Rodrigues A., et al. Costs of illness and care in Parkinson's Disease: An evaluation in six countries. European Neuropsychopharmacology 2011; 21(2), 180-191. doi:10.1016/j.euroneuro.2010.08.002 Go to original source... Go to PubMed...
  13. Spottke A. E., Reuter M., Machat O., Bornschein B., von Campenhausen S., Berger K., et al. Cost of illness and its predictors for Parkinson's disease in Germany. Pharmacoeconomics 2005; 23, 817-836. Go to original source... Go to PubMed...
  14. Tamás G., Gulácsi L., Bereczki D., Baji P., Takáts A., Brodszky V., et al. Quality of life and costs in Parkinson's disease: a cross sectional study in Hungary. PLoS ONE 2014; 9(9), e107704. doi:10.1371/journal.pone.0107704 Go to original source... Go to PubMed...
  15. Suh D. Ch., Pahwa R., Mallya U. Treatment patterns and associated costs with Parkinson's disease levodopa induced dyskinesia. Journal of the Neurological Sciences 2012; 319(1-2), 24-31. doi:10.1016/j.jns.2012.05.029 Go to original source... Go to PubMed...
  16. Kaltenboeck A., Johnson S. J., Davis M. R., et al. Direct costs and survival of medicare beneficiaries with early and advanced parkinson's disease. Parkinsonism 2012; 18(4), 321-326 doi:10.1016/j.parkreldis.2011.11.015 Go to original source... Go to PubMed...
  17. Cordato D. J., Schwartz R., Abbott E., et al. A comparison of health-care costs involved in treating people with and without Parkinson's disease in Southern Sydney, New South Wales, Australia. Journal of Clinical Neuroscience 2006; 13(6), 655-658. doi:10.1016/j.jocn.2005.09.006 Go to original source... Go to PubMed...
  18. Chan D. K., Cordato D., Karr M., et al. Prevalence of Parkinson's disease in Sydney. Acta Neurol Scand. 2005; 111, 7-11. Go to original source... Go to PubMed...
  19. Kwak M. Social demographic characteristics and direct medical costs for patients with Parkinson's disease in Korea: big data analysis from the national health insurance claims dataset. Value in Health 2015; 18(7), A751. doi:10.1016/j.jval.2015.09.2906 Go to original source...
  20. OECD 2016. Available at: https://www.oecd.org/ (accessed 20. 11. 2015).




Czech and Slovak Pharmacy

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.